Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension

The main purpose of this prospective, multicentre, french observational study is to analyse the evolution of pulse pressure (PP) and to identify its prognostic factors in hypertensive patients three months after initiation of a new hypertensive therapy. The PP is defined as the difference between systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with essential arterial hypertension needing a new antihypertensive therapy
A patient was included by the physician only if he/she had agreed after being informed about the study

Exclusion criteria

Treatment and study plan

Micardis®

Drug

Other names: Telmisartan

Other hypertensives

Drug

Primary outcomes

Changes from baseline in pulse pressure

Time frame: Up to 3 months after start of treatment
Number of patients with adverse drug reactions

Time frame: Up to 3 months after start of treatment

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy

Important dates

Study start: 2001
Primary completion: 2002
First posted: Jul 29, 2014
Registry last updated: Jul 29, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed